Decades of strict price controls drove R&D investment out of Europe – and Germany is now doubling down with even tougher measures. @Dleonard_DC and @KMAndersonDC break down what this means as the U.S. considers similar policies, and why we can't afford to repeat Europe's mistakes. More here: weworkforhealth.org/post/eur…

IP misconceptions often dominate the drug affordability debate. In reality, patents and data exclusivity support the cost and risk of developing new medicines and ultimately enable the generic and biosimilar competition that expands access. Read more: weworkforhealth.org/post/myt…

As policymakers weigh MFN and other pricing proposals, experts warn of potential ripple effects across the U.S. biopharma ecosystem, from early-stage research to patient access. New insights from leaders across biotech, venture capital and policy highlight the risks to investment, innovation and long-term competitiveness. Read more and watch the full discussion: weworkforhealth.org/post/pro…

Policies intended to accelerate access can undermine innovation if they weaken the intellectual property systems that sustain drug development in the first place. Henry Hadad of @bmsnews examines how recent EU IP reforms could reshape investment decisions and ultimately limit patient access to future therapies: weworkforhealth.org/post/pro…

New Jersey is home to one of the world's leading life sciences hubs – supporting hundreds of thousands of jobs and fueling billions in economic activity. MFN pricing puts this all at risk and would limit patient access to medicines, reduce R&D investment, and slow the next generation of cures. More from WWFH’s @DLeonard_DC and @ChrissyButeas of @HINJ_ORG: weworkforhealth.org/post/mos…

The Administration promised to reduce drug costs, yet MFN would almost certainly undermine its ability to keep that promise. Here's what the experts are saying: weworkforhealth.org/post/fac…

Some policymakers want to double down on the IRA with MFN pricing. @USCSchaeffer analysis has shown why that’s risky: Government price controls don’t reliably lower costs for seniors, but they do weaken U.S. innovation and boost global competitors like China. weworkforhealth.org/post/mos…

Europe spent years undermining its own pharma sector with misguided price controls – and is now scrambling to recover. The lesson for U.S. policymakers is clear: don't make the same mistakes. Check out our latest blog to learn more: weworkforhealth.org/post/eur…

.@RepHoulahan: "China is, if not closing the gap, in some cases has closed the gap and has exceeded our capabilities as well." Read WWFH's blog for more key takeaways from our recent briefing: weworkforhealth.org/post/eur…

As WWFH Executive Director @DLeonard_DC warned in a recent op-ed, “today’s public investments in basic science are tomorrow’s cures.” With China advancing through sustained state-backed investment, the U.S. cannot afford to lose ground in biopharma innovation. biospace.com/policy/opinion-…

A major milestone for American investment: Biopharma companies have now committed more than $500B to expand manufacturing capabilities and strengthen the U.S. supply chain. Explore the latest activity in our U.S. Biopharma Investment Watch: weworkforhealth.org/investin…

Fresh insights from @McKinsey and TD Cowen examine China’s rapid rise as an innovation leader, driving 29% of the global pipeline. What does this mean for U.S. biotech? Read more here: weworkforhealth.org/post/new…

A strong year for European drug innovation still lagged well behind the U.S. New data highlights the risk of Washington adopting MFN pricing from foreign countries: weworkforhealth.org/post/eur…

Forward-thinking public policy is essential to ensure global medical innovation continues to thrive in U.S. states rather than moving overseas. Read this recent op-ed by @DebbieHartBioNJ and @DLeonard_DC: binje.com/op-ed-how-n-j-can-…

"We have to take this seriously." Experts issue warning, recommendations on China's effort to dominate drug innovation. Inside the WWFH-hosted discussion: weworkforhealth.org/post/chi…

MFN pricing models pose significant risks to American patients and workers, and policies like GLOBE and GUARD strengthen foreign competitors at the expense of U.S. leadership. Read our statement: weworkforhealth.org/post/sta…

ICYMI: WWFH responded to the administration’s plan to set maximum fair prices for IPAY 2027 selected drugs, warning that such price controls may harm patients and reduce innovation. Read more here: weworkforhealth.org/post/we-…

WWFH is hosting a timely briefing on China’s rising dominance in the global biopharma industry. Hear from experts about the widespread risks this poses to the biopharma sector, global leadership, and national security. REGISTER HERE: docs.google.com/forms/d/e/1F…

For #IntellectualProperty Month, WWFH Executive Director @DLeonard_DC spoke with Laura Schoppe of @TechPipeline on U.S. innovation. As China’s biopharma grows, Laura explains why protecting IP is vital to U.S. leadership. Watch the interview: weworkforhealth.org/post/fro…

It’s Intellectual Property Month! 🎉 We’re celebrating the key role #IPRights play in protecting innovation and keeping America competitive. Explore our IP webpage to learn more: weworkforhealth.org/ip